|
AstraZeneca licenses experimental asthma drug
Philadelphia Business Journal (blog) AstraZeneca entered into an exclusive global licensing agreement Thursday for an experimental asthma drug being developed by Synairgen, a United Kingdom biopharmaceutical company. Under the terms of the deal, AstraZeneca (NYSE: AZN) will make an … |
View full post on asthma – Google News